Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

This study is comparing two traditional Chinese medicines — Icaritin soft capsules and Huachansu tablets — as first-line treatments for people with liver cancer (hepatocellular carcinoma) that cannot be surgically removed and has poor prognostic biomarkers. The goal is to find which is more effective in this specific patient group. **You may be eligible if...** - You are 18 years or older with confirmed liver cancer that cannot be surgically removed - You have specific blood biomarker levels (high AFP, low TNF-α, high IFN-γ) that match the study criteria - You have not previously received any systemic treatment for liver cancer **You may NOT be eligible if...** - Your tumor takes up more than 70% of your liver - You have moderate-to-severe fluid buildup in the abdomen (ascites) or around the lungs - You have had major surgery recently - You have other serious liver, kidney, or heart conditions Talk to your doctor to see if this trial is right for you.